Stocktoria

SI-BONE, Inc. SIBN

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2018-10-17 · LEI

SI-BONE, Inc. (SIBN) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $200.9M at a -9.4% net margin.

Chart by TradingView
52/100
Stocktoria Quality Score · grade C
6/9
Piotroski F — financial health
1.52
Altman Z″ — distress risk · grey
Dividend yield · no dividend
-2.95
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
5 2 4 3 2 4 5 6 20182019202020212022202320242025
Altman Z″
3.70 -1.10 4.67 1.11 -3.34 1.23 0.77 1.52 20182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$19.00 as of 2026-08-01 · +14% 1y
$12.39$19.7252-wk

Beneish M-score: -2.95 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$769M
Net margin 5y avg-35.9%
Return on equity 5y avg-31.8%
Beta0.7
Employees376

Analyst price target

$24.12 +27% vs last
· 8 analysts
target range $18.00 – $32.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net sold -$501,742 on the open market · 12 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 9y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 78%
Net marginstronger than 41%
Return on equitystronger than 48%
Revenue growthstronger than 80%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · grey zone

ComponentValue
Working capital / assets0.8
Retained earnings / assets-1.887
EBIT / assets-0.094
Equity / liabilities2.909

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
SIBNSI-BONE, Inc.6/91.52+20.2%
TMCITREACE MEDICAL CONCEPTS, INC.2/9-1.79+1.6%
HTFLHeartflow, Inc.4/9-2.45+39.9%
CERSCERUS CORP4/9-13.54+16.1%
KIDSORTHOPEDIATRICS CORP4/92.67+15.4%
LMATLEMAITRE VASCULAR INC6/98.1837.9+13.5%
STIMNeuronetics, Inc.4/9-10.38+99.2%

All Manufacturing companies →

About SI-BONE, Inc.

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

FAQ

Is SIBN financially healthy?

SI-BONE, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.

Does SIBN pay a dividend?

No, SI-BONE, Inc. does not currently pay a dividend.

How profitable is SIBN?

In FY2025, SI-BONE, Inc. had a net margin of -9.4% and a return on equity of -10.6%.

What is the analyst price target for SIBN?

The average Wall-Street price target for SI-BONE, Inc. is $24.12, about 27.0% above the recent price, from 8 analysts.

Is SIBN a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on SI-BONE, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.